<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD05650000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P10276</UniProt_ID>
  <Seq_Length>462</Seq_Length>
  <Molecule_Weight>50771</Molecule_Weight>
  <KEGG_ID>hsa:5914</KEGG_ID>
  <Orthology_ID>K08527</Orthology_ID>
  <EBI_ID>EBI-413374</EBI_ID>
  <Function_Summary>Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence of ligand, the RXR-RAR heterodimers associate with a multiprotein complex containing transcription corepressors that induce histone acetylation, chromatin condensation and transcriptional suppression. On ligand binding, the corepressors dissociate from the receptors and associate with the coactivators leading to transcriptional activation. RARA plays an essential role in the regulation of retinoic acid-induced germ cell development during spermatogenesis. Has a role in the survival of early spermatocytes at the beginning prophase of meiosis. In Sertoli cells, may promote the survival and development of early meiotic prophase spermatocytes. In concert with RARG, required for skeletal growth, matrix homeostasis and growth plate function (By similarity). Regulates expression of target genes in a ligand-dependent manner by recruiting chromatin complexes containing MLL5. Mediates retinoic acid-induced granulopoiesis.</Function_Summary>
  <Pfam_ID>PF00104:Hormone_recep@@PF00105:zf-C4</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>0</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Nuclear receptor subfamily 1 group B member 1</Alias>
      <Alias>RAR-alpha</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with retinoic acid, 3,7-dimethyl-9-(2,6,-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid.</Detail>
      <Keyword>Retinoic acid binding</Keyword>
      <Ontology_ID>GO:0001972</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a specific domain of a protein.</Detail>
      <Keyword>Protein domain specific binding</Keyword>
      <Ontology_ID>GO:0019904</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with an extracellular or intracellular messenger to initiate a change in cell activity.</Detail>
      <Keyword>Receptor activity</Keyword>
      <Ontology_ID>GO:0004872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with zinc (Zn) ions.</Detail>
      <Keyword>Zinc ion binding</Keyword>
      <Ontology_ID>GO:0008270</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with DNA of a specific nucleotide composition, e.g. GC-rich DNA binding, or with a specific sequence motif or type of DNA e.g. promotor binding or rDNA binding.</Detail>
      <Keyword>Sequence-specific DNA binding</Keyword>
      <Ontology_ID>GO:0043565</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with retinoic acid to initiate a change in cell activity. Retinoic acid is one of the forms of vitamin A.</Detail>
      <Keyword>Retinoic acid receptor activity</Keyword>
      <Ontology_ID>GO:0003708</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a nonidentical protein to form a heterodimer.</Detail>
      <Keyword>Protein heterodimerization activity</Keyword>
      <Ontology_ID>GO:0046982</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively with a retinoic acid-responsive element, a variable direct repeat of the sequence PuGGTCA spaced by five nucleotides (DR5) found in the promoters of retinoic acid-responsive genes, to which retinoic acid receptors bind.</Detail>
      <Keyword>Retinoic acid-responsive element binding</Keyword>
      <Ontology_ID>GO:0044323</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with one or more specific sites on a receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function.</Detail>
      <Keyword>Receptor binding</Keyword>
      <Ontology_ID>GO:0005102</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a transcription factor, any protein required to initiate or regulate transcription.</Detail>
      <Keyword>Transcription factor binding</Keyword>
      <Ontology_ID>GO:0008134</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with a steroid hormone to initiate a change in cell activity.</Detail>
      <Keyword>Steroid hormone receptor activity</Keyword>
      <Ontology_ID>GO:0003707</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any metal ion.</Detail>
      <Keyword>Metal ion binding</Keyword>
      <Ontology_ID>GO:0046872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a repressing transcription factor and also with the basal transcription machinery in order to stop, prevent, or reduce the frequency, rate or extent of transcription. Cofactors generally do not bind DNA, but rather mediate protein-protein interactions between repressive transcription factors and the basal transcription machinery.</Detail>
      <Keyword>Transcription corepressor activity</Keyword>
      <Ontology_ID>GO:0003714</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any subunit of protein kinase A.</Detail>
      <Keyword>Protein kinase A binding</Keyword>
      <Ontology_ID>GO:0051018</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a activating transcription factor and also with the basal transcription machinery in order to increase the frequency, rate or extent of transcription. Cofactors generally do not bind DNA, but rather mediate protein-protein interactions between activating transcription factors and the basal transcription machinery.</Detail>
      <Keyword>Transcription coactivator activity</Keyword>
      <Ontology_ID>GO:0003713</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with protein kinase B, an intracellular kinase that is important in regulating glucose metabolism.</Detail>
      <Keyword>Protein kinase B binding</Keyword>
      <Ontology_ID>GO:0043422</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Any molecular function by which a gene product interacts selectively with DNA (deoxyribonucleic acid).</Detail>
      <Keyword>DNA binding</Keyword>
      <Ontology_ID>GO:0003677</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with DNA that is assembled into chromatin.</Detail>
      <Keyword>Chromatin DNA binding</Keyword>
      <Ontology_ID>GO:0031490</Ontology_ID>
    </Funtion>
  </Function_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>A change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of stimulus by estradiol, a C18 steroid hormone hydroxylated at C3 and C17 that acts as a potent estrogen.</Detail>
      <Keyword>Response to estradiol stimulus</Keyword>
      <Ontology_ID>GO:0032355</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate, or extent of interleukin-5 production.</Detail>
      <Keyword>Positive regulation of interleukin-5 production</Keyword>
      <Ontology_ID>GO:0032754</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of cellular DNA-dependent transcription.</Detail>
      <Keyword>Negative regulation of transcription, DNA-dependent</Keyword>
      <Ontology_ID>GO:0045892</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a retinoic acid stimulus.</Detail>
      <Keyword>Cellular response to retinoic acid</Keyword>
      <Ontology_ID>GO:0071300</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate, or extent of tumor necrosis factor production.</Detail>
      <Keyword>Negative regulation of tumor necrosis factor production</Keyword>
      <Ontology_ID>GO:0032720</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process involved in the assembly of the RNA polymerase II preinitiation complex (PIC) at an RNA polymerase II promoter region of a DNA template, resulting in the subsequent synthesis of RNA from that promoter. The initiation phase includes PIC assembly and the formation of the first few bonds in the RNA chain, including abortive initiation, which occurs when the first few nucleotides are repeatedly synthesized and then released. Promoter clearance, or release, is the transition between the initiation and elongation phases of transcription.</Detail>
      <Keyword>Transcription initiation from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0006367</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate, or extent of interleukin-13 production.</Detail>
      <Keyword>Positive regulation of interleukin-13 production</Keyword>
      <Ontology_ID>GO:0032736</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the rate or extent of cell proliferation.</Detail>
      <Keyword>Positive regulation of cell proliferation</Keyword>
      <Ontology_ID>GO:0008284</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the rate or extent of binding, the selective interaction of a molecule with one or more specific sites on another molecule.</Detail>
      <Keyword>Positive regulation of binding</Keyword>
      <Ontology_ID>GO:0051099</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of granulocyte differentiation.</Detail>
      <Keyword>Negative regulation of granulocyte differentiation</Keyword>
      <Ontology_ID>GO:0030853</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of stimulus by an estrogen, C18 steroid hormones that can stimulate the development of female sexual characteristics.</Detail>
      <Keyword>Cellular response to estrogen stimulus</Keyword>
      <Ontology_ID>GO:0071391</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The recognition and removal of an apoptotic cell by a neighboring cell or by a phagocyte.</Detail>
      <Keyword>Apoptotic cell clearance</Keyword>
      <Ontology_ID>GO:0043277</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of T-helper 2 cell differentiation.</Detail>
      <Keyword>Positive regulation of T-helper 2 cell differentiation</Keyword>
      <Ontology_ID>GO:0045630</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process of introducing a phosphate group on to a protein.</Detail>
      <Keyword>Protein phosphorylation</Keyword>
      <Ontology_ID>GO:0006468</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any series of molecular signals generated as a consequence of an estrogen binding to its receptor.</Detail>
      <Keyword>Estrogen receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0030520</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate, or extent of interleukin-4 production.</Detail>
      <Keyword>Positive regulation of interleukin-4 production</Keyword>
      <Ontology_ID>GO:0032753</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Regulation of transcription</Keyword>
      <Ontology_ID>GO:0045449</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Transcription</Keyword>
      <Ontology_ID>GO:0006350</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate, or extent of interferon-gamma production. Interferon-gamma is also known as type II interferon.</Detail>
      <Keyword>Negative regulation of interferon-gamma production</Keyword>
      <Ontology_ID>GO:0032689</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of transcription from the RNA polymerase II promoter.</Detail>
      <Keyword>Positive regulation of transcription from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0045944</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the rate or extent of progression through the cell cycle.</Detail>
      <Keyword>Positive regulation of cell cycle</Keyword>
      <Ontology_ID>GO:0045787</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>369</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>77</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>96</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>219</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MASNSSSCPTPGGGHLNGYPVPPYAFFFPPMLGGLSPPGALTTLQHQLPVSGYSTPSPATIETQSSSSEEIVPSPPSPPPLPRIYKPCFVCQDKSSGYHYGVSACEGCKGFFRRSIQKNMVYTCHRDKNCIINKVTRNRCQYCRLQKCFEVGMSKESVRNDRNKKKKEVPKPECSESYTLTPEVGELIEKVRKAHQETFPALCQLGKYTTNNSSEQRVSLDIDLWDKFSELSTKCIIKTVEFAKQLPGFTTLTIADQITLLKAACLDILILRICTRYTPEQDTMTFSDGLTLNRTQMHNAGFGPLTDLVFAFANQLLPLEMDDAETGLLSAICLICGDRQDLEQPDRVDMLQEPLLEALKVYVRKRRPSRPHMFPKMLMKITDLRSISAKGAERVITLKMEIPGSMPPLIQEMLENSEGLDTLSGQPGGGGRDGGGLAPPPGSCSPSLSPSSNRSSPATHSP</Protein_Seq>
    <DNA_Seq>GTGCCTCTTGCAGCAGCCTAACCCAGAAGCAGGGGGGAATCCTGAATCGAGCTGAGAGGGCTTCCCCGGTTCTCCTGGGAACCCCATCGGCCCCCTGCCAGCACACACCTGAGCAGCATCACAGGACATGGCCCCCTCAGCCACCTAGCTGGGGCCCATCTAGGAGTGGCATCTTTTTTGGTGCCCTGAAGGCCAGCTCTGGACCTTCCCAGGAAAAGTGCCAGCTCACAGAACTGCTTGACCAAAGGACCGGCTCTTGAGACATCCCCCAACCCACCTGGCCCCCAGCTAGGGTGGGGGCTCCAGGAGACTGAGATTAGCCTGCCCTCTTTGGACAGCAGCTCCAGGACAGGGCGGGTGGGCTGACCACCCAAACCCCATCTGGGCCCAGGCCCCATGCCCCGAGGAGGGGTGGTCTGAAGCCCACCAGAGCCCCCTGCCAGACTGTCTGCCTCCCTTCTGACTGTGGCCGCTTGGCATGGCCAGCAACAGCAGCTCCTGCCCGACACCTGGGGGCGGGCACCTCAATGGGTACCCGGTGCCTCCCTACGCCTTCTTCTTCCCCCCTATGCTGGGTGGACTCTCCCCGCCAGGCGCTCTGACCACTCTCCAGCACCAGCTTCCAGTTAGTGGATATAGCACACCATCCCCAGCCACCATTGAGACCCAGAGCAGCAGTTCTGAAGAGATAGTGCCCAGCCCTCCCTCGCCACCCCCTCTACCCCGCATCTACAAGCCTTGCTTTGTCTGTCAGGACAAGTCCTCAGGCTACCACTATGGGGTCAGCGCCTGTGAGGGCTGCAAGGGCTTCTTCCGCCGCAGCATCCAGAAGAACATGGTGTACACGTGTCACCGGGACAAGAACTGCATCATCAACAAGGTGACCCGGAACCGCTGCCAGTACTGCCGACTGCAGAAGTGCTTTGAAGTGGGCATGTCCAAGGAGTCTGTGAGAAACGACCGAAACAAGAAGAAGAAGGAGGTGCCCAAGCCCGAGTGCTCTGAGAGCTACACGCTGACGCCGGAGGTGGGGGAGCTCATTGAGAAGGTGCGCAAAGCGCACCAGGAAACCTTCCCTGCCCTCTGCCAGCTGGGCAAATACACTACGAACAACAGCTCAGAACAACGTGTCTCTCTGGACATTGACCTCTGGGACAAGTTCAGTGAACTCTCCACCAAGTGCATCATTAAGACTGTGGAGTTCGCCAAGCAGCTGCCCGGCTTCACCACCCTCACCATCGCCGACCAGATCACCCTCCTCAAGGCTGCCTGCCTGGACATCCTGATCCTGCGGATCTGCACGCGGTACACGCCCGAGCAGGACACCATGACCTTCTCGGACGGGCTGACCCTGAACCGGACCCAGATGCACAACGCTGGCTTCGGCCCCCTCACCGACCTGGTCTTTGCCTTCGCCAACCAGCTGCTGCCCCTGGAGATGGATGATGCGGAGACGGGGCTGCTCAGCGCCATCTGCCTCATCTGCGGAGACCGCCAGGACCTGGAGCAGCCGGACCGGGTGGACATGCTGCAGGAGCCGCTGCTGGAGGCGCTAAAGGTCTACGTGCGGAAGCGGAGGCCCAGCCGCCCCCACATGTTCCCCAAGATGCTAATGAAGATTACTGACCTGCGAAGCATCAGCGCCAAGGGGGCTGAGCGGGTGATCACGCTGAAGATGGAGATCCCGGGCTCCATGCCGCCTCTCATCCAGGAAATGTTGGAGAACTCAGAGGGCCTGGACACTCTGAGCGGACAGCCGGGGGGTGGGGGGCGGGACGGGGGTGGCCTGGCCCCCCCGCCAGGCAGCTGTAGCCCCAGCCTCAGCCCCAGCTCCAACAGAAGCAGCCCGGCCACCCACTCCCCGTGACCGCCCACGCCACATGGACACAGCCCTCGCCCTCCGCCCCGGCTTTTCTCTGCCTTTCTACCGACCATGTGACCCCGCACCAGCCCTGCCCCCACCTGCCCTCCCGGGCAGTACTGGGGACCTTCCCTGGGGGACGGGGAGGGAGGAGGCAGCGACTCCTTGGACAGAGGCCTGGGCCCTCAGTGGACTGCCTGCTCCCACAGCCTGGGCTGACGTCAGAGGCCGAGGCCAGGAACTGAGTGAGGCCCCTGGTCCTGGGTCTCAGGATGGGTCCTGGGGGCCTCGTGTTCATCAAGACACCCCTCTGCCCAGCTCACCACATCTTCATCACCAGCAAACGCCAGGACTTGGCTCCCCCATCCTCAGAACTCACAAGCCATTGCTCCCCAGCTGGGGAACCTCAACCTCCCCCCTGCCTCGGTTGGTGACAGAGGGGGTGGGACAGGGGCGGGGGGTTCCCCCTGTACATACCCTGCCATACCAACCCCAGGTATTAATTCTCGCTGGTTTTGTTTTTATTTTAATTTTTTTGTTTTGATTTTTTTAATAAGAATTTTCATTTTAAGCACATTTATACTGAAGGAATTTGTGCTGTGTATTGGGGGGAGCTGGATCCAGAGCTGGAGGGGGTGGGTCCGGGGGAGGGAGTGGCTCGGAAGGGGCCCCCACTCTCCTTTCATGTCCCTGTGCCCCCCAGTTCTCCTCCTCAGCCTTTTCCTCCTCAGTTTTCTCTTTAAAACTGTGAAGTACTAACTTTCCAAGGCCTGCCTTCCCCTCCCTCCCACTGGAGAAGCCGCCAGCCCCTTTCTCCCTCTGCCTGACCACTGGGTGTGGACGGTGTGGGGCAGCCCTGAAAGGACAGGCTCCTGGCCTTGGCACTTGCCTGCACCCACCATGAGGCATGGAGCAGGGCAGAGCAAGGGCCCCGGGACAGAGTTTTCCCAGACCTGGCTCCTCGGCAGAGCTGCCTCCCGTCAGGGCCCACATCATCTAGGCTCCCCAGCCCCCACTGTGAAGGGGCTGGCCAGGGGCCCGAGCTGCCCCCACCCCCGGCCTCAGCCACCAGCACCCCCATAGGGCCCCCAGACACCACACACATGCGCGTGCGCACACACACAAACACACACACACTGGACAGTAGATGGGCCGACACACACTTGGCCCGAGTTCCTCCATTTCCCTGGCCTGCCCCCCACCCCCAACCTGTCCCACCCCCGTGCCCCCTCCTTACCCCGCAGGACGGGCCTACAGGGGGGTCTCCCCTCACCCCTGCACCCCCAGCTGGGGGAGCTGGCTCTGCCCCGACCTCCTTCACCAGGGGTTGGGGCCCCTTCCCCTGGAGCCCGTGGGTGCACCTGTTACTGTTGGGCTTTCCACTGAGATCTACTGGATAAAGAATAAAGTTCTATTTATTCTAAAAAAAAAAAAAAAAAA</DNA_Seq>
  </Molecule_Seq>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleus</CellLocal>
      <Ontology_ID>GO:0005634</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytoplasm</CellLocal>
      <Ontology_ID>GO:0005737</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleoplasm</CellLocal>
      <Ontology_ID>GO:0005654</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cell surface</CellLocal>
      <Ontology_ID>GO:0009986</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nuclear chromatin</CellLocal>
      <Ontology_ID>GO:0000790</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>RARA</Gene_Name>
    <Gene_Alias>NR1B1</Gene_Alias>
    <Gene_ID>5914</Gene_ID>
    <Genbank_ACCN>NM_000964</Genbank_ACCN>
    <Protein_ACCN>NP_000955</Protein_ACCN>
    <HGNC_ID>9864</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/5914</Gene_URL>
    <UCSC_ID>uc002huk.2</UCSC_ID>
    <EMBL_ID>ENSG00000131759</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>Q8IXJ9</Uniprot_ID>
      <Gene_Name>ASXL1</Gene_Name>
      <EBI_ID>EBI-1646500</EBI_ID>
      <PPI_EBI_URL>EBI-413374,EBI-1646500</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P59598</Uniprot_ID>
      <Gene_Name>Asxl1</Gene_Name>
      <EBI_ID>EBI-5743705</EBI_ID>
      <PPI_EBI_URL>EBI-413374,EBI-5743705</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q15910</Uniprot_ID>
      <Gene_Name>EZH2</Gene_Name>
      <EBI_ID>EBI-530054</EBI_ID>
      <PPI_EBI_URL>EBI-413374,EBI-530054</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q96EB6</Uniprot_ID>
      <Gene_Name>SIRT1</Gene_Name>
      <EBI_ID>EBI-1802965</EBI_ID>
      <PPI_EBI_URL>EBI-413374,EBI-1802965</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q2M1K9</Uniprot_ID>
      <Gene_Name>ZNF423</Gene_Name>
      <EBI_ID>EBI-950016</EBI_ID>
      <PPI_EBI_URL>EBI-413374,EBI-950016</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>O75376</Uniprot_ID>
      <Gene_Name>NCOR1</Gene_Name>
      <EBI_ID>EBI-347233</EBI_ID>
      <PPI_EBI_URL>EBI-413374,EBI-347233</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q8IZD2</Uniprot_ID>
      <Gene_Name>MLL5</Gene_Name>
      <EBI_ID>EBI-2689959</EBI_ID>
      <PPI_EBI_URL>EBI-413374,EBI-2689959</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P19793</Uniprot_ID>
      <Gene_Name>RXRA</Gene_Name>
      <EBI_ID>EBI-78598</EBI_ID>
      <PPI_EBI_URL>EBI-413374,EBI-78598</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Juvenile Myelomonocytic Leukemia</Disease_Name>
      <Disease_Detail>Juvenile Myelomonocytic Leukemia</Disease_Detail>
      <Disease_DB>JVN004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/juvenile_myelomonocytic_leukemia?search=RARA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Breast Cancer</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>BRS047</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/breast_cancer?search=RARA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cutaneous Mastocytosis</Disease_Name>
      <Disease_Detail>Cutaneous Mastocytosis</Disease_Detail>
      <Disease_DB>CTN014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cutaneous_mastocytosis?search=RARA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Aleukemic Leukemia Cutis</Disease_Name>
      <Disease_Detail>Aleukemic Leukemia Cutis</Disease_Detail>
      <Disease_DB>ALK003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/aleukemic_leukemia_cutis?search=RARA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Caudal Regression Syndrome</Disease_Name>
      <Disease_Detail>Caudal Regression Syndrome</Disease_Detail>
      <Disease_DB>CDL003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/caudal_regression_syndrome?search=RARA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Neuroblastoma</Disease_Name>
      <Disease_Detail>Neuroblastoma</Disease_Detail>
      <Disease_DB>NRB001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/neuroblastoma?search=RARA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acute Promyelocytic Leukemia</Disease_Name>
      <Disease_Detail>Acute Promyelocytic Leukemia</Disease_Detail>
      <Disease_DB>ACT119</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acute_promyelocytic_leukemia?search=RARA#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Crystal structure of RARalpha ligand binding domain in complex with the inverse agonist BMS493 and a corepressor fragment</PDB_Title>
      <PDB_ID>3KMZ</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KMZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A unique secondary-structure switch controls constitutive gene repression by retinoic acid receptor.</PubMed_Title>
      <Author>le Maire, A., et al.</Author>
      <Journal>Nat.Struct.Mol.Biol.(2010)17:801-807</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20543827?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of RARalpha ligand binding domain in complex with an agonist ligand (Am580) and a coactivator fragment</PDB_Title>
      <PDB_ID>3KMR</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KMR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A unique secondary-structure switch controls constitutive gene repression by retinoic acid receptor.</PubMed_Title>
      <Author>le Maire, A., et al.</Author>
      <Journal>Nat.Struct.Mol.Biol.(2010)17:801-807</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20543827?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of a mixed agonist-bound RAR-alpha and antagonist-bound RXR-alpha heterodimer ligand binding domains</PDB_Title>
      <PDB_ID>3A9E</PDB_ID>
      <Resolution>2.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3A9E</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The phantom effect of the rexinoid LG100754: Structural and functional insights</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF THE RXR/RAR DNA-BINDING DOMAIN HETERODIMER IN COMPLEX WITH THE RETINOIC ACID RESPONSE ELEMENT DR1</PDB_Title>
      <PDB_ID>1DSZ</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1DSZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the RXR-RAR DNA-binding complex on the retinoic acid response element DR1.</PubMed_Title>
      <Author>Rastinejad, F., et al.</Author>
      <Journal>EMBO J.(2000)19:1045-1054</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10698945?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF A HETERODIMERIC COMPLEX OF RAR AND RXR LIGAND-BINDING DOMAINS</PDB_Title>
      <PDB_ID>1DKF</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1DKF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains.</PubMed_Title>
      <Author>Bourguet, W., et al.</Author>
      <Journal>Mol.Cell(2000)5:289-298</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10882070?dopt=Abstract</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko05200</Pathway_ID>
      <Pathway_Title>Pathways in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05221</Pathway_ID>
      <Pathway_Title>Acute myeloid leukemia</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05202</Pathway_ID>
      <Pathway_Title>Transcriptional misregulation in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05221</Pathway_ID>
      <Pathway_Title>Acute myeloid leukemia</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05200</Pathway_ID>
      <Pathway_Title>Pathways in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05202</Pathway_ID>
      <Pathway_Title>Transcriptional misregulation in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>All alpha proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.b.cdh.b.b.c.html</SCOP_URL>
    <CATH_Class>Class 1: Mainly Alpha</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1dkf</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Type>Ligand-induced conformational change</Site_Type>
    </AllostericSite>
  </AllostericSite_List>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>